Litcius/Paper detail

The Role of Non-Coding RNAs in Breast Cancer Drug Resistance

Jinhai Tian, Shihai Liu, Chuan-yang Yu, Ligang Wu, Libin Wang

2021Frontiers in Oncology23 citationsDOIOpen Access PDF

Abstract

Breast cancer (BC) is one of the commonly occurring malignancies in females worldwide. Despite significant advances in therapeutics, the mortality and morbidity of BC still lead to low survival and poor prognosis due to the drug resistance. There are certain chemotherapeutic, endocrine, and target medicines often used for BC patients, including anthracyclines, taxanes, docetaxel, cisplatin, and fluorouracil. The drug resistance mechanisms of these medicines are complicated and have not been fully elucidated. It was reported that non-coding RNAs (ncRNAs), such as micro RNAs (miRNA), long-chain non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) performed key roles in regulating tumor development and mediating therapy resistance. However, the mechanism of these ncRNAs in BC chemotherapeutic, endocrine, and targeted drug resistance was different. This review aims to reveal the mechanism and potential functions of ncRNAs in BC drug resistance and to highlight the ncRNAs as a novel target for achieving improved treatment outcomes for BC patients.

Topics & Concepts

Drug resistancemicroRNABreast cancerDrugMechanism (biology)MedicineChemotherapeutic drugsCancerCisplatinLong non-coding RNABioinformaticsEndocrine systemDocetaxelCancer researchBiologyPharmacologyOncologyInternal medicineRNAChemotherapyGeneGeneticsEpistemologyPhilosophyHormoneCircular RNAs in diseasesCancer-related molecular mechanisms researchMicroRNA in disease regulation